Status:
COMPLETED
Non Transplantable Recurrence After Percutaneous Thermal Ablation of HCC
Lead Sponsor:
University Hospital, Montpellier
Conditions:
HCC
Eligibility:
All Genders
18+ years
Brief Summary
Percutaneous thermal ablation (PTA), resection and liver transplantation (LT) are the standard curative options for hepatocellular carcinoma (HCC). LT yields the best long-term outcomes but is limited...
Detailed Description
Consecutive patients undergoing PTA for HCC between January 2015 and December 2020 were included. Data were collected from our prospective database. This study was approved by our institutional review...
Eligibility Criteria
Inclusion
- Inclusion criteria :
- HCC diagnosed by histopathology or by EASL imaging criteria
- HCC ≤30mm, 1 - 3 tumor nodules, follow-up\<3 months
- no prior or combined treatment with intra-arterial therapy
- potentially transplantable patient (ie, ≤70yr, AFP-score≤2 (7), no macroscopic portal vein invasion or extra-hepatic metastasis, no major comorbidity precluding LT).
- Exclusion criteria:
- \- age \< 18 years
Exclusion
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 30 2020
Estimated Enrollment :
213 Patients enrolled
Trial Details
Trial ID
NCT05202184
Start Date
January 1 2015
End Date
December 30 2020
Last Update
February 8 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Uhmontpellier
Montpellier, France, 34295